Deferasirox, an Iron-Chelating Agent, as Salvage Therapy for Rhinocerebral Mucormycosis
Open Access
- 1 November 2006
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (11), 3968-3969
- https://doi.org/10.1128/aac.01065-06
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Deferiprone iron chelation as a novel therapy for experimental mucormycosisJournal of Antimicrobial Chemotherapy, 2006
- Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and ManagementClinical Microbiology Reviews, 2005
- Iron-chelating therapy with the new oral agent ICL670 (Exjade®)Best Practice & Research Clinical Haematology, 2005
- Combination Therapy with Amphotericin B Lipid Complex and Caspofungin Acetate of Disseminated Zygomycosis in Diabetic Ketoacidotic MiceAntimicrobial Agents and Chemotherapy, 2005
- Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effectKidney International, 1994
- Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.JCI Insight, 1993